• Vaccine-tech startup hopes it can make lightning strike again

    Crain’s Detroit covers Iaso Therapeutics. The interview reports on the history and funding of Iaso. View the article from Crain's Detroit Business

    Published On: April 29, 2024
  • A new tool to fight cancer, infections, addiction

    A soccer ball-shaped, nanoparticle-sized vaccine delivery platform called Q-Beta might hold the key to unlocking treatments for any number of viruses and diseases — from cancers to infections and even opioid addiction — thanks to the work of a research team that got its start at Michigan State University.

    Published On: March 13, 2024
  • Iaso 2024 Conference Schedule

    Iaso will be attending several industry conferences in 2024. Look for us at these upcoming conferences. World Vaccine Congress Washington 2024 April 1-4, 2024 Walter E. Washington Convention Center, [...]

    Published On: February 29, 2024
  • Iaso Selected for the Renaissance Venture Capital Startup Hotlist

    Iaso Therapeutics has been included on the @Renaissance Venture Capital Spring 2023 Startup Hotlist! The Hotlist features some of the most promising early-stage companies from the Midwest, curated from hundreds of recommendations from VC [...]

    Published On: June 10, 2023
  • Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financing

    Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the company’s $1.25M Series Seed Preferred round of financing.

    Published On: January 25, 2023
  • Iaso Therapeutics Receives Grant from the National Science Foundation for Next-Generation Vaccine Research

    The nearly $1 million grant will fund vaccine delivery research targeting infectious diseases and cancer EAST LANSING, Mich., March 14, 2022 -- Iaso Therapeutics, a research program focused on the development of novel technologies [...]

    Published On: March 14, 2022
  • Iaso Therapeutics Awarded Competitive Grant from the National Institute of Allergy and Infectious Diseases

    Small Business Innovation Research Program Provides Seed Funding for R&D East Lansing, MI, 07/15/2021 – Iaso Therapeutics, INC. has been awarded a National Institute of Allergy and Infectious Diseases (NIAID) Small Business Innovation Research [...]

    Published On: February 11, 2022
  • Building Better Vaccines: Iaso Therapeutics

    Vaccines have dominated the news. With the COVID-19 pandemic, stories about vaccines have been a daily occurrence. They range from concerns about safety to vaccination rates and distribution. They highlight the amazing science that [...]

    Published On: June 1, 2021
  • Iaso Therapeutics secures investment from Michigan State University’s Student Venture Capital Fund

    East Lansing, MI – Iaso has been selected to receive a $10k investment by the Michigan State University (MSU) Student Venture Capital Fund (MSU SVCF). This spring, Iaso participated in an annual class project [...]

    Published On: April 26, 2021
  • Iaso Therapeutics Invited to TRECS Workshop

    East Lansing, MI – Iaso Therapeutics (Iaso) has received a selective invitation to participate in the National Cancer Institute (NCI) Translational Resources to Expedite Commercialization Success Workshop (TRECS WORKSHOP). Iaso will participate in the [...]

    Published On: February 25, 2021
  • ‘An immense opportunity’: How LEAP wants Greater Lansing to become a med-tech hub

    Craig Lyons Lansing State Journal LANSING – When Herbert Kavunja joined Iaso Therapeutics as its chief scientist and sole employee, he faced a steep learning curve. He had to figure out how to write [...]

    Published On: February 8, 2021
  • Iaso Therapeutics Receives Phase I SBIR Grant from the National Cancer Institute

    Iaso Therapeutics received a Phase I SBIR grant from the National Cancer Institute (NCI). The grant is to study the feasibility of developing a cancer vaccine against breast cancer including triple negative breast cancer [...]

    Published On: October 15, 2020
  • Iaso Therapeutics Receives Phase I SBIR Grant from the National Science Foundation

    Iaso Therapeutics received a Phase I SBIR grant from the National Science Foundation (NSF). The grant is to study the feasibility of commercializing Iaso’s mutant Qβ (mQβ) virus-like particle. The mQβ particles are a [...]

    Published On: June 20, 2019